Candel Therapeutics CADL
NASDAQ CADL
$9.40 +0.05 (+0.53%)
As of: Nov 11, 2026 · 10:16 AM EST

Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)

Updated

Candel Therapeutics' Preferred Stock Liabilities was $49.06 million in Q2 2021, unchanged from $49.06 million a year earlier and unchanged from the prior quarter.

Analysis

Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

From Q2 2020 onward, Candel Therapeutics has reported Preferred Stock Liabilities for 5 quarters.

  • Per Business Quant data, CADL's Preferred Stock Liabilities in the three quarters before Q2 2021 was $49.06 million (Q1 2021), $49.06 million (Q4 2020) and $49.06 million (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Candel Therapeutics 711.71 Mn 108.61 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 49.06 Mn
Mar 31, 2021 49.06 Mn
Dec 31, 2020 49.06 Mn
Sep 30, 2020 49.06 Mn
Jun 30, 2020 49.06 Mn
API Access

Candel Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CADL&period=max&api_key=YOUR_API_KEY